Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMARETI: Mass Drug Administration and Targeted Control Against Malaria Transmission
NCT07281443Active, not recruiting
- Sponsor
- Institut de Recherche pour le Développement
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dihydroartemisinin + piperaquine and primaquine in malaria and parasitemia (2 arms), sponsored by Institut de Recherche pour le Développement. Primary endpoints: Plasmodium falciparum carriage reservoir and Odds ratio of P. falciparum infection. Started Sep 2024; status: active, not recruiting.
02
Drugs
dihydroartemisinin + piperaquineprimaquine
03
Conditions
malariaparasitemia
Beyond the preview
Go deeper on NCT07281443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281443.